Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Inclusion Criteria: * Be ≥18 years of age (or the higher legal age in the jurisdiction in which the study is taking place) at the time of informed consent * Has documented diagnosis of MM according to the IMWG diagnostic criteria (Rajkumar 2011). * Teclistamab or Talquetamab + Tocilizumab: has received 2 or more prior MM therapies including a PI, IMiD and CD38 antibody. * Teclistamab + Oral Dexamethasone: has received 1 or more prior MM therapies including a PI, IMiD and/or CD38 antibody. * Teclistamab or Talquetamab + Tocilizumab: has an ECOG performance status (Oken 1982) of 0 to 1. Teclistamab + Oral Dexamethasone: has an ECOG performance status (Oken 1982) of 0 to 2. * Measurable disease at screening, as assessed by local laboratory, defined by any of the following: * Serum M-protein level ≥0.5 g/dL; or * Urine M-protein level ≥200 mg/24 hours; or * Light chain MM without measurable M-protein in the serum or the urine: serum free light chain (sFLC) ≥10 mg/dL and abnormal serum immunoglobulin kappa lambda FLC ratio. * For participants without measurable disease in the serum, urine, or involved FLC, presence of plasmacytomas (≥2 cm). * Human immunodeficiency virus-positive participants are eligible if they meet all of the following: * No detectable viral load (i.e., \<50 copies/mL) at screening * CD4+ count \>300 cells/mm3 at screening * No acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection within 6 months of screening * Receiving highly active antiretroviral therapy (HAART). Any changes in HAART due to resistance/progression should occur at least 3 months prior to enrollment. A change in HAART due to toxicity is allowed up to 4 weeks prior to enrollment. * Adequate organ system function * Body weight \>35 kg. * A participant of childbearing potential must have a negative highly sensitive serum (β-hCG) at screening and within 72 hours of the start of study treatment and must agree to further serum or urine pregnancy tests during the study. * A participant must agree to abide by protocol defined contraceptive requirements for the duration of the study including avoiding donating gametes for specified period of time. * A participant must sign an ICF indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study. * A participant is required to stay within 60 minutes of transportation to the site and remain in the company of a competent adult at all times until 48 hours following administration of all doses within the teclistamab step-up dosing schedules * A participant is required to stay within 30 minutes of transportation to the site and remain in the company of a competent adult at all times until 48 hours following administration of all doses within the talquetamab step-up dosing schedule * A participant must agree to carry the study participant identification wallet card at all times. * A participant must comply with all the protocol requirement procedures, including measuring and recording of body temperature and blood oxygen saturation twice daily (≥8 hours apart) during the first 2 cycles of teclistamab or talquetamab treatment and coming to the study site for safety assessments. * A participant and the accompanying competent adult must be made aware of the presenting sign sand symptoms of teclistamab- or talquetamab- associated toxicities, including but not limited to CRS, ICANS, infections, etc. The accompanying competent adult must watch the participant at all times for teclistamab- or talquetamab- associated toxicities, until 48 hours after the first treatment dose of teclistamab or talquetamab. Exclusion Criteria: * Has a rapidly progressing disease per investigator assessment. * Has plasma cell leukemia (\>2.0×10\^9/L plasma cells by standard differential), Waldenström's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or primary amyloid light-chain amyloidosis. * Has known active CNS involvement or exhibits clinical signs of meningeal involvement of MM. * Has risk factors for developing clinically significant TLS and requiring management with increased hydration, allopurinol, or rasburicase. * Has myelodysplastic syndrome or active malignancies (ie, progressing or requiring treatment change in the last 12 months) other than RRMM. The only allowed exceptions are: * Any malignancy that was not progressing nor requiring treatment change in the last 12 months. * Malignancies treated within the last 12 months and considered at very low risk for recurrence: * Non-muscle invasive bladder cancer (solitary Ta-PUNLMP or low grade, \<3 cm, no CIS). * Skin cancer (non-melanoma or melanoma). * Noninvasive cervical cancer. * Breast cancer: adequately treated lobular carcinoma in situ or ductal carcinoma in situ, localized breast cancer and receiving antihormonal agents. * Localized prostate cancer (M0, N0) with a Gleason Score ≤7a, treated locally only (RP/RT/focal treatment). * Other malignancy that is considered at minimal risk of recurrence. * Has Grade ≥3 hematologic AEs or Grade ≥3, clinically significant non-hematologic AEs. * Has fever or active infection (bacterial, viral, or uncontrolled systemic fungal) at time of study enrollment. * Has active autoimmune disease or a documented history of autoimmune disease with the exception of vitiligo, type I diabetes, and prior autoimmune thyroiditis that is currently euthyroid based on clinical symptoms and laboratory testing. * Has clinically significant coagulopathy that would increase the risk of bleeding in the setting of cytopenia. * Shows a deterioration in neurologic status, including mental status changes such as confusion or increased somnolence. * Has psychiatric disorders (eg, alcohol or drug abuse), dementia, or altered mental status that would compromise the ability to provide informed consent or comply with the clinica